- Verastem recently reported their Q4 and full-year 2021 earnings that revealed substantial headway in their pipeline and on the balance sheet.
- Verastem secured up to $150M in non-dilutive funding from Oxford Finance. Now, the company expects their cash runway to last through 2025.
- The company announced they completed enrollment in Part A of RAMP 201 of VS-6766 +/- Defactinib in LGSOC. They anticipate report results from Part A in Q2.
- The Part A of RAMP 202 VS-6766 +/- Defactinib for KRAS G12V Mutant NSCLC is also fully enrolled. Verastem expects to report some data in the second half of this year.
- I discuss my plans to move my VSTM out of mothball and back into the Compounding Healthcare Bio Boom Portfolio.
For further details see:
Verastem: Time To Take My Position Out Of Mothball